Fig. 11 | Scientific Reports

Fig. 11

From: ASCL2 contributes to clinical assessments of breast cancer and mediates tumor progression via the interaction with CLDN3

Fig. 11

Pan-cancer analysis of ASCL2. (A) The differential expressions of ASCL2 between normal and tumor samples across 31 cancer types in TCGA database; (B) The effects of ASCL2 expressive levels on the prognosis of patients across 31 cancer types; (C) The effects of ASCL2 expressive levels on the immune infiltration levels across 31 cancer types. *P < 0.05, **P < 0.01, ***P < 0.001; NS, not statistic difference.

Back to article page